← Back to The Absolute Effect
Prostate cancer · Oligometastatic prostate cancer · MDT+intermittent hormone therapy

EXTEND

Does MDT added to intermittent hormone therapy improve disease control?

Phase II randomized basket trial; prostate intermittent-hormone basket n=87; up to 5 metastases.

Arms / design

Phase II randomized basket trial; prostate intermittent-hormone basket n=87; up to 5 metastases.

Outcome visualization · source-reported data

Progression events

PFS HR 0.25 (95% CI 0.12–0.55); p<0.001

MDT + hormone therapy
30%
Hormone therapy alone
64%

Visualization reflects reported outcomes; it does not itself generate an NNT or establish an overall-survival benefit.

Key result

Progression events: 13/43 with MDT+hormone therapy vs 28/44 with hormone therapy alone. Median PFS not reached vs 15.8 months.

Interpretation and limitations

https://pubmed.ncbi.nlm.nih.gov/37022702/

Primary source

undefined

Read source →

Current-practice context · reviewed 14 October 2026

EXTEND provides randomized phase II evidence that metastasis-directed therapy added to intermittent hormone therapy can improve progression control in selected oligometastatic prostate cancer, but it does not establish an overall-survival benefit or replace systemic therapy. Use lesion number, imaging sensitivity, disease biology, prior systemic exposure and patient goals to select candidates; MDT remains a shared-decision/clinical-trial discussion rather than a universal rule.

EXTEND primary source ↗ · Current guideline guidance ↗